Fisher Asset Management LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO

Fisher Asset Management LLC decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 381,745 shares of the biopharmaceutical company’s stock after selling 35,771 shares during the quarter. Fisher Asset Management LLC owned approximately 0.31% of Halozyme Therapeutics worth $19,858,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Wealth Preservation Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth about $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics in the first quarter worth approximately $33,000. Employees Retirement System of Texas purchased a new position in Halozyme Therapeutics in the second quarter worth approximately $34,000. Brooklyn Investment Group grew its holdings in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 670 shares in the last quarter. Finally, Asset Management One Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $98,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 2.8%

HALO opened at $64.66 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $46.26 and a one year high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market capitalization of $7.60 billion, a P/E ratio of 13.61, a price-to-earnings-growth ratio of 0.37 and a beta of 0.95. The business’s 50-day simple moving average is $68.61 and its 200-day simple moving average is $64.20.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.27 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, November 28th. Finally, The Goldman Sachs Group raised their target price on Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 18th. Seven investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $75.10.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total value of $150,480.00. Following the transaction, the director owned 44,952 shares in the company, valued at $3,382,188.48. The trade was a 4.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the sale, the chief financial officer directly owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 103,625 shares of company stock worth $7,446,727. Insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.